lonigutamab
lonigutamab: sourced relationships with 2 companies · 1 clinical trial tracked.
lonigutamab evidence translation
What we can confirm
1 tracked trial
What it means
More than one company relationship is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about lonigutamab, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Thyroid Eye Disease ("TED")Thyroid Eye Disease
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| ALUMIS INC. (ALMS) Thyroid Eye Disease ("TED") | Phase 1/Phase 2 |
| ACELYRIN, Inc. (SLRN) | Phase 1/Phase 2 |
Clinical Trial Registry Records (1)
A Phase 1/2, Adaptive, Multiple Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of Lonigutamab in Subjects With Thyroid Eye Disease (TED)
Primary endpoint: Incidence and characterization of nonserious treatment emergent adverse events (TEAEs)
InterventionalRandomizedquadruple31 enrolledStarted 2023-02Completion 2025-0511 sites · Australia, United StatesACELYRIN Inc.
Frequently asked questions
Which companies have sourced relationships with lonigutamab?
lonigutamab has dated SEC/FDA relationship records for ALUMIS INC., ACELYRIN, Inc..
How many clinical trials involve lonigutamab?
BioSniper tracks 1 clinical trial involving lonigutamab.